Insmed (INSM) Free Cash Flow (2010 - 2026)
Insmed (INSM) posted quarterly Free Cash Flow of -$226.2 million for Q1 2026, up 16.88% year-over-year from -$193.5 million in Q1 2025, and up 12.79% quarter-over-quarter from -$259.4 million in Q4 2025.
Insmed (INSM) Free Cash Flow (2010 - 2026) Analysis & Trends
Insmed's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$226.2 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 16.88% year-over-year to -$226.2 million; the TTM figure through Mar 2026 stood at -$891.2 million (down 16.65% YoY), while the FY2025 annual figure was -$937.1 million, down 38.72% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$226.2 million, up from -$259.4 million in the prior quarter.
- The five-year high for Free Cash Flow was -$98.2 million in Q3 2022, with the low at -$272.2 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$149.7 million (2023), against an average of -$164.6 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow grew 27.8% in 2022, then tumbled 94.31% in 2025.
- Insmed's Free Cash Flow stood at -$100.0 million in 2022, then slumped by 32.97% to -$133.0 million in 2023, then plunged by 45.35% to -$193.3 million in 2024, then sank by 34.21% to -$259.4 million in 2025, then gained by 12.79% to -$226.2 million in 2026.
- Business Quant data shows INSM's Free Cash Flow at -$226.2 million in Q1 2026, -$259.4 million in Q4 2025, and -$196.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.09 Mn |
| Jun 30, 2026 | -95.09 Mn |
| Mar 31, 2026 | -226.22 Mn |
| Mar 31, 2026 | -226.22 Mn |
| Dec 31, 2025 | -259.38 Mn |
| Dec 31, 2025 | -259.38 Mn |
| Sep 30, 2025 | -196.54 Mn |
| Sep 30, 2025 | -196.54 Mn |
| Jun 30, 2025 | -209.05 Mn |
| Jun 30, 2025 | -209.05 Mn |
| Mar 31, 2025 | -272.16 Mn |
| Mar 31, 2025 | -272.16 Mn |
| Dec 31, 2024 | -193.27 Mn |
| Dec 31, 2024 | -193.27 Mn |
| Sep 30, 2024 | -190.99 Mn |
| Sep 30, 2024 | -190.99 Mn |
| Jun 30, 2024 | -107.59 Mn |
| Jun 30, 2024 | -107.59 Mn |
| Mar 31, 2024 | -183.70 Mn |
| Mar 31, 2024 | -183.70 Mn |